12:00 AM
 | 
Jul 23, 2012
 |  BC Week In Review  |  Company News  |  Other News

Novavax, PATH infectious news

Not-for-profit PATH awarded Novavax about $2 million to support a dose-ranging Phase II trial of Novavax's RSV-F vaccine to vaccinate women of childbearing age against respiratory syncytial virus (RSV). The...

Read the full 127 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >